Complete clearance lasts for a very long time due to knockout of resident memory T cells within the skin,’ said the study’s ...
In the second half of his Maui Derm recap, George Martin, MD, founder and program director of the meeting, highlights new ...
Oral roflumilast showed potential as a nonbiologic systemic therapy for moderate to severe psoriasis, offering an alternative ...
Takeda Pharmaceutical Co. announced that its oral psoriasis drug zasocitinib proved safe and effective in late-stage trials, ...
A new study published in the Journal of American Medical Association showed that psoriasis patients who used antibiotics had ...
A phase 3 trial shows that apremilast, an oral phosphodiesterase 4 inhibitor, improves symptoms, disease severity, and ...
The results position Takeda, which acquired its therapy in one of the industry’s larger single-drug acquisitions, to ...
Compared to Sotyktu (deucravacitinib), which was approved by the FDA for plaque psoriasis in 2022 and brought in sales of ...
Japan's Takeda Pharmaceutical said on Thursday its experimental pill for a type of skin disease, developed using artificial ...
SNGX READ THE FULL SNGX RESEARCH REPORT Business Update Positive Results for SGX302 in Cohort 3 of Phase 2a Psoriasis Trial ...
Soligenix reports positive Phase 2a extension results for SGX302 gel in psoriasis, showing improved skin scores and strong ...
Psoriasis causes your body to make new skin cells too quickly. These cells tend to pile up and form spots, bumps, and thick scaly patches called plaques that can be uncomfortable. Scientists think ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback